Methysergide use in specific populations

Methysergide
SANSERT® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Clinical Trials on Methysergide
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Use In Specific Populations

Pregnancy Category: X

Sansert® (methysergide maleate) is contraindicated in pregnancy due to its oxytocic actions.

Nursing Mothers

There are no specific studies on the use of Sansert® (methysergide maleate) in nursing mothers. Ergot alkaloids, in general, appear in mothers’ milk. Sansert® (methysergide maleate) is a semi-synthetic compound structurally related to ergotamine, and thus it may appear in breast milk. Ergot alkaloids have been reported to cause nausea, vomiting, diarrhea and weakness in the nursing infant and suppression of prolactin secretion and lactation in the mother.

Because of the potential for serious adverse reactions in nursing infants from Sansert® (methysergide maleate), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

References

Adapted from the FDA Package Insert.